Merseyside Inter Agency Drug Misuse Database

Halton DAT

Quarter 4 2007/08

**Lloyd Baron, Martin Chandler,
Jim McVeigh**

www.cph.org.uk/iad

Contacts:
Martin Chandler
IAD Manager
Centre for Public Health
Faculty of Health & Applied Social Sciences
Liverpool John Moores University
Castle House
North Street
L3 2AY

(0151) 231 4531
m.chandler@ljmu.ac.uk

Lloyd Baron
IAD Researcher

(0151) 231 4521
L.R.Baron@ljmu.ac.uk

www.cph.org.uk/iad

Contents

National Drug Treatment Monitoring System (NDTMS)   **13**

Connexions   **16**

Combined Datasets   **18**

Cross Matched Datasets   **19**

Introduction

The Inter Agency Drug Misuse Database (IAD), established by Merseyside Drug (and Alcohol) Action Teams, Merseyside Police and the Public Health Sector (now Centre for Public Health) in 1997, supports the need for local information on drug misuse. In particular the IAD aims to:

- Provide comprehensive reporting of problem drug users' (PDUs') characteristics including a range of demographics and the types of drugs used.
- Reflect levels of service and intervention activity.
- Assist in D(A)AT's (and other responsible bodies) performance management.
- Facilitate the planning and development of services and interventions for PDUs.
- Identify gaps in service provision and delivery, as well as under-served groups as specified by the National Treatment Agency and Department of Health and by the Centre for Public Health, through interrogation of available data.
- Highlight changes in levels, demographics and characteristics of drug user populations.
- Report back to both individual D(A)ATs and service providers in the form of audits and quarterly reports as well as responding to ad hoc requests.
- Provide summary reporting on an annual basis.

To enable the above the IAD collects data from as many agencies in contact with drug users as possible and is continually seeking to expand the range and scope of data providers. Data are currently collected from criminal justice services, needle exchange schemes (both pharmacy and agency-based), the National Drug Treatment Monitoring System (NDTMS) and Connexions (young people).

Data considerations

Analysis of data depends on the provision of attributable information. Each service provider records first and last initials, date of birth and gender, for each individual they record a contact with. The combination of these details provides an identifier (attributor) for each individual (e.g.: HF07/12/1974M). This is a nationally recognised system and allows individuals to be tracked through different service providers and across time whilst retaining an acceptable degree of anonymity. The attributor is essential to avoid double counting of individuals both within and across datasets, as well as enabling us to match across datasets. The D(A)AT referred to is the D(A)AT of contact unless otherwise stated.

The IAD will *only* be reporting attributable data for each dataset. In the past, report deadlines have been missed due to data arriving too late to be cleaned and analysed in time, or more often because the data requires a great deal of cleaning and validation before analysis. These reports are useful only if they can arrive within timelines useful to D(A)ATs (ie: in time for NTA quarterly submissions). For this reason, reports will now be sent out according to a strict timetable, with each quarter's report to be sent in the first week of the third month following the close of the reporting period. Any data that is missing or non-attributable will not be included in the report.

> Year-to-Date figures will be provided for the current financial year, and will incorporate updated figures from previous quarters. The figures are calculated by aggregating successive quarterly datasets to omit double counting of those who present to services in each quarter. Year-to-Date data will be the most accurate reflection of annual service activity and will override previous quarterly data.

The Centre for Public Health will continue to work closely with service providers and D(A)ATs in order to improve both the timeliness and quality of monitoring data provided to the IAD. Many service providers are turning to electronic recording of data and it is hoped this will vastly improve the quality of the data as systems improve.

ARREST REFERRAL (AR)
Quarter 4 (2007/08)

Introduction

Raw data are provided by the Drug Intervention Programme (DIP) Team based at the Centre for Public Health, Liverpool John Moores University. The data supplied are for validated contacts within specified D(A)AT areas and are aggregated to one person per D(A)AT area. Individuals may therefore appear more than once within the final dataset if they have been seen in more than one D(A)AT area, but only once for each D(A)AT area within the reporting period.

Table 1: Individuals assessed, by Gender & Age Group

Gender	n	%
Male	25	83.3
Female	5	16.7
Age Group		
Under 18	0	0.0
18-19	1	3.3
20-24	3	10.0
25-29	6	20.0
30-34	11	36.7
35-39	4	13.3
40-44	5	16.7
45+	0	0.0
Total	30	100

Table 2: Year to Date, by Gender & Age Group

	Gender					
	Male		Female		*Total in Age Group*	
Age Group	n	%	n	%	*n*	%
Under 18	1	1.0	0	0.0	1	>1
18-19	9	9.2	2	7.7	11	8.9
20-24	19	19.4	4	15.4	23	18.5
25-29	21	21.4	3	11.5	24	19.4
30-34	23	23.5	9	34.6	32	25.8
35-39	14	14.3	3	11.5	17	13.7
40-44	11	11.2	2	7.7	13	10.5
45+	0	0.0	3	11.5	3	2.4
Total	98	100	26	100	124	100

Table 3: Reported Main Drug(s) of Use, by Frequency of Use

Drug of Use	Daily	Weekly
Amphetamines	2	1
Benzodiazepines	0	0
Cannabis	6	0
Crack	14	1
Cocaine	3	1
Ecstasy	0	1
Heroin	17	2
Methadone	1	0

NB: The complexity of the drug profiles reported through arrest referral is such that we have decided the best way of reporting the data is to provide figures for the number of people reporting Daily or Weekly use of each drug. Where "Main drug" is provided in the original data it does not always match the other substances reported as being used daily; consequently, this method of reporting should provide a more accurate picture of drug use as reported through Arrest Referral rather than simply stating the "Main Drug". However it should be noted that some people may report several drugs being used and will therefore be counted in the figures for each drug they report. For this reason totals are not provided.

SYRINGE EXCHANGE SERVICES
Quarter 4 (2007/08)

Introduction

Data are collected directly from syringe exchange providers. Analysis of syringe exchange data allows performance monitoring of harm reduction services at both D(A)AT and service provider level.

AGENCY SYRINGE EXCHANGE

Table 4: Individuals by Gender

New Clients	n	%
Male	28	84.8
Female	5	15.2
Total	33	100
All Clients		
Male	122	90.4
Female	13	9.6
Total	135	100

Table 5: Individuals by Gender: Steroids Users Omitted

New Clients	n	%
Male	7	58.3
Female	5	41.7
Total	12	100
All Clients		
Male	43	76.8
Female	13	23.2
Total	56	100

Table 6: Individuals by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	3	9.1	4	3.0
20-24	15	45.5	32	23.7
25-29	7	21.2	25	18.5
30-34	3	9.1	31	23.0
35-39	5	15.2	22	16.3
40-44	0	0.0	14	10.4
45+	0	0.0	7	5.2
Total	33	100	135	100

Table 7: Individuals by Age Group: Steroid Users omitted

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	0	0.0	0	0.0
20-24	4	33.3	7	12.5
25-29	3	25.0	7	12.5
30-34	1	8.3	12	21.4
35-39	4	33.3	15	26.8
40-44	0	0.0	10	17.9
45+	0	0.0	5	8.9
Total	12	100	56	100

Table 8: Gender by Age Group of Individuals

| Age Group | Gender | | | |
| | Male | | Female | |
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	4	3.3	0	0.0
20-24	29	23.8	3	23.1
25-29	21	17.2	4	30.8
30-34	29	23.8	2	15.4
35-39	20	16.4	2	15.4
40-44	14	11.5	0	0.0
45+	5	4.1	2	15.4
Total	122	100	13	100

Table 9: Gender by Age Group: Steroid Users omitted

| Age Group | Gender | | | |
| | Male | | Female | |
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	0	0.0	0	0.0
20-24	4	9.3	3	23.1
25-29	3	7.0	4	30.8
30-34	10	23.3	2	15.4
35-39	13	30.2	2	15.4
40-44	10	23.3	0	0.0
45+	3	7.0	2	15.4
Total	43	100	13	100

Table 10: Year to Date, by Gender & Age Group

Age Group	Male		Female		Total in Age Group	
	n	%	n	%	n	%
Under 18	1	<1	0	0.0	1	<1
18-19	18	5.3	0	0.0	18	4.9
20-24	75	22.0	3	10.7	78	21.1
25-29	67	19.6	7	25.0	74	20.1
30-34	63	18.5	5	17.9	68	18.4
35-39	54	15.8	4	14.3	58	15.7
40-44	39	11.4	4	14.3	43	11.7
45+	24	7.0	5	17.9	29	7.9
Total	341	100	28	100	369	100

Table 11: Year to Date, by Gender & Age Group: Steroid Users Omitted

Age Group	Male		Female		Total in Age Group	
	n	%	n	%	n	%
Under 18	0	0.0	0	0.0	0	0.0
18-19	3	2.9	0	0.0	3	2.3
20-24	8	7.8	3	10.7	11	8.5
25-29	12	11.8	7	25.0	19	14.6
30-34	15	14.7	5	17.9	20	15.4
35-39	29	28.4	4	14.3	33	25.4
40-44	20	19.6	4	14.3	24	18.5
45+	15	14.7	5	17.9	20	15.4
Total	102	100	28	100	130	100

Table 12: Main Drug of Use for New Agency Syringe Exchange Clients, by Gender

	Gender			
	Male		Female	
Drug of Use	**n**	**%**	**n**	**%**
Amphetamines	1	3.6	0	0.0
Benzodiazepines	0	0.0	0	0.0
Cocaine	0	0.0	0	0.0
Crack	0	0.0	0	0.0
Heroin	5	17.9	3	60.0
Methadone	0	0.0	0	0.0
Steroids	21	75.0	0	0.0
Other	1	3.6	2	40.0
Total	28	100	5	100

Please Note: Due to changes in reporting methods we will now only report drug of use for new clients. Information on drug of use for all clients is available on request.

Table 13: Main Drug of Use for New Agency Syringe Exchange Clients, by Age Group

	Ampheta-mine		Benzodi-azepine		Cocaine		Crack		Heroin		Methadone		Steroids	
Age Group	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**
Under 18	-	-	-	-	-	-	-	-	-	-	-	-	-	-
18-19	-	-	-	-	-	-	-	-	-	-	-	-	3	14.0
20-24	-	-	-	-	-	-	-	-	2	25	-	-	11	52.0
25-29	-	-	-	-	-	-	-	-	2	25	-	-	4	19.0
30-34	-	-	-	-	-	-	-	-	1	12.5	-	-	2	10.0
35-39	1	100	-	-	-	-	-	-	3	37.5	-	-	1	5.0
40-44	-	-	-	-	-	-	-	-	-	-	-	-	-	-
45+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total	1	100	-	-	-	-	-	-	8	100	-	-	21	100

* % Totals are by Drug, not Age Group.

PHARMACY SYRINGE EXCHANGE

Table 14: Individuals by Gender

New Clients	n	%
Male	28	87.5
Female	4	12.5
Total	32	100
All Clients		
Male	62	91.2
Female	6	8.8
Total	68	100

Table 15: Individuals by Age Group

	New Clients		All Clients	
Age Group	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	0	0.0	0	0.0
20-24	8	25.0	9	13.2
25-29	11	34.4	15	22.1
30-34	5	15.6	13	19.1
35-39	3	9.4	13	19.1
40-44	1	3.1	8	11.8
45+	4	12.5	10	14.7
Total	32	100	68	100

Table 16: Year to Date, by Gender & Age Group

	Gender				Total in Age Group	
	Male		Female			
Age Group	n	%	n	%	n	%
Under 18	0	0.0	0	0.0	0	0.0
18-19	1	>1	0	0.0	1	>1
20-24	19	13.9	0	0.0	19	12.5
25-29	28	20.4	9	60.0	37	24.3
30-34	19	13.9	4	26.7	23	15.1
35-39	29	21.2	1	6.7	30	19.7
40-44	25	18.2	0	0.0	25	16.4
45+	16	11.7	1	6.7	17	11.2
Total	137	100	15	100	152	100

COMBINED PHARMACY AND AGENCY SYRINGE EXCHANGE

Analyses here are based on an aggregated combination of Agency and Pharmacy-based datasets for the reporting period. Data are aggregated by attributor and D(A)AT to one person per D(A)AT area.

Table 17: Individuals in Syringe Exchange, by Gender

New Clients	n	%
Male	56	86.2
Female	9	13.8
Total	65	100
All Clients		
Male	176	90.7
Female	18	9.3
Total	194	100

Table 18: Individuals in Syringe Exchange, by Gender: Steroid Users Omitted*

New Clients	n	%
Male	35	79.5
Female	9	20.5
Total	44	100
All Clients		
Male	97	84.3
Female	18	15.7
Total	115	100

*Only known steroid users, based on Agency SES data, have been omitted.

Table 19: Individuals in Syringe Exchange, by Age Group

	New Clients		All Clients	
Age Group	**n**	**%**	**n**	**%**
Under 18	0	0.0	0	0.0
18-19	3	4.6	4	2.1
20-24	23	35.4	41	21.1
25-29	18	27.7	37	19.1
30-34	8	12.3	42	21.6
35-39	8	12.3	33	17.0
40-44	1	1.5	21	10.8
45+	4	6.2	16	8.2
Total	65	100	194	100

Table 20: Individuals in Syringe Exchange by Age Group: Steroid Users Omitted

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	0	0.0	0	0.0
20-24	12	27.3	16	13.9
25-29	14	31.8	19	16.5
30-34	6	13.6	23	20.0
35-39	7	15.9	26	22.6
40-44	1	2.3	17	14.8
45+	4	9.1	14	12.2
Total	44	100	115	100

Table 21: Year to Date, by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	1	>1	0	0.0	1	>1
18-19	19	4.2	0	0.0	19	3.9
20-24	94	20.8	3	7.9	97	19.8
25-29	91	20.2	13	34.2	104	21.3
30-34	77	17.1	8	21.1	85	17.4
35-39	73	16.2	5	13.2	78	16.0
40-44	59	13.1	4	10.5	63	12.9
45+	37	8.2	5	13.2	42	8.6
Total	451	100	38	100	489	100

Table 22: Total Syringes Provided

	Agency	Pharmacy	Total (Q)	Year to Date
Barrels	6,327	1,256	7,583	36,403

NB: We will no longer be reporting needle returns as it is not possible to accurately calculate them from the data available. Total Syringes include exchanges by non-attributable individuals.

National Drug Treatment Monitoring System (NDTMS)
Quarter 4 (2007/08)

Background

The NDTMS is the official method for measuring the extent and nature of structured drug treatment in England and Wales. The system is commissioned by the NTA and is operated through nine regional centres – corresponding to the nine government offices for the regions.

Data here are aggregated to one individual per D(A)AT. Individuals presenting in more than one D(A)AT within the quarter's time period will therefore be represented more than once in the original data. The D(A)AT referred to is D(A)AT of treatment.

New Clients

Figures presented here for "new" clients are calculated using the triage date. Those individuals triaged within the reporting period are taken as new clients for this report. However, it should be noted that these individuals may have been triaged, or in contact with treatment services, before this period.

Table 23: Individuals in Contact with Treatment Services, by Gender

New Clients	n	%
Male	55	76.4
Female	17	23.6
Total	72	100
All Clients		
Male	648	72.8
Female	241	27.2
Total	889	100

Table 24: Year to Date, by Gender

New Clients	n	%
Male	272	74.3
Female	94	25.7
Total	366	100
All Clients		
Male	760	71.0
Female	310	29.0
Total	1070	100

Table 25: Individuals in Contact with Treatment Services, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	4	5.5	43	4.8
18-19	1	1.4	31	3.4
20-24	7	9.7	88	9.9
25-29	15	20.8	140	15.7
30-34	16	22.2	190	21.3
35-39	16	22.2	188	21.1
40-44	8	11.1	112	12.6
45+	5	6.9	97	10.9
Total	72	100	889	100

Table 26: Year to Date, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	28	7.7	62	5.8
18-19	15	4.1	40	3.7
20-24	55	15.0	146	13.6
25-29	56	15.3	197	18.4
30-34	70	19.1	240	22.4
35-39	60	16.4	179	16.7
40-44	44	12.0	99	9.3
45+	38	10.4	107	10.0
Total	366	100	1070	100

Table 27: Ethnicity of Individuals in Contact with Treatment Services

Ethnicity	New Clients		All Clients	
	n	%	n	%
White British	69	95.8	870	98.08
White Irish	1	1.3	2	>1
Other White	1	1.3	2	>1
White & Black Caribbean	1	1.3	3	>1
White & Asian	0	0.0	1	>1
Other Asian	0	0.0	1	>1
Caribbean	0	0.0	3	>1
Chinese	0	0.0	1	>1
Unknown	0	0.0	6	>1
Total	72	100	889	100

Table 28: Individuals in Contact with Treatment Services, by Main Drug of Use

Drug of Use	New Clients		All Clients	
	n	%	n	%
Heroin	35	48.6	417	46.9
Methadone	4	5.5	60	6.7
Other Opiates	4	5.5	20	2.2
Benzodiazepine	0	0.0	6	>1
Amphetamines	1	1.3	44	4.9
Cocaine	9	12.5	121	13.6
Crack	4	5.5	51	5.7
Ecstasy	0	0.0	7	>1
Cannabis	14	19.4	152	17.1
Other/Unknown	1	1.3	11	1.2
Total	*72*	*100*	*889*	*100*

CONNEXIONS
Quarter 4 (2007/08)

Background

Connexions provide a support service for young people, aged 13-19. The Greater Merseyside Connexions Partnership provides data presented here.

Table 29: Individuals in Contact with Connexions, by Gender

Gender	n	%
Male	21	60.0
Female	14	40.0
Total	35	100

Table 30: Year to Date, by Gender

Gender	n	%
Male	27	58.7
Female	19	41.3
Total	46	100

Table 31: Individuals in Contact with Connexions, by Age

Age Group	n	%
16	4	11.4
17	16	45.7
18	10	28.6
19	5	14.3
Total	35	100

Table 32: Year to Date, by Age

Age Group	n	%
16	5	10.9
17	18	39.1
18	13	28.3
19	10	21.7
Total	46	100

Table 33: Individuals in Contact with Connexions by Drug/Alcohol Problem

Substance	n	%
Alcohol/Other*	10	28.6
Drugs	25	71.4
Total	35	100

*"Other" is generally used to refer to solvents although this is not necessarily always the case.

Table 34: Year to Date, by Drug/Alcohol problem

Substance	n	%
Alcohol/Other*	11	23.9
Drugs	35	76.1
Total	46	100

*"Other" is generally used to refer to solvents although this is not necessarily always the case.

COMBINED DATASETS
Quarter 4 (2007/08)

Introduction

Data presented here are drawn from a combination of datasets relating to Arrest Referrals, Probation, Syringe Exchange (Agency and Pharmacy), NDTMS and Connexions. The combined data are aggregated on attributor and D(A)AT area of intervention (except Probation, which is based on residence), to produce overall figures for numbers of individuals in contact with services reporting to the IAD. Figures presented here will not necessarily reflect the combined totals of data presented earlier as duplicate attributors are removed. These figures should not be taken as a measure of prevalence of problem drug users, but reflects the total number of problem drug users in contact with a range of agencies. Further information on the processes of data manipulation, aggregation and analysis is available from the IAD Manager.

Table 35: Total Problem Drug Users reported to the IAD, by Gender and Age Group

Gender	n	%
Male	801	74.9
Female	268	25.1
Age Group		
Under 18	72	6.7
18-19	49	4.6
20-24	162	15.2
25-29	207	19.4
30-34	234	21.9
35-39	171	16.0
40-44	95	8.9
45+	79	7.4
Total	1069	100

Table 36: Year to Date, by Gender and Age Group

|	Gender					
	Male		Female		Total in Age Group	
Age Group	n	%	n	%	n	%
Under 18	50	4.1	20	5.5	70	4.4
18-19	73	6.0	12	3.3	85	5.3
20-24	195	15.9	33	9.0	228	14.3
25-29	213	17.4	55	15.0	268	16.8
30-34	222	18.1	86	23.5	308	19.3
35-39	222	18.1	62	16.9	284	17.8
40-44	144	11.7	48	13.1	192	12.1
45+	107	8.7	50	13.7	157	9.9
Total	1226	100	366	100	1592	100

CROSS-MATCHED DATASETS
Quarter 4 (2007/08)

Data are shown for the crossover between each type of Syringe Exchange and NDTMS, separately, during the current reported quarter. For the purposes of this analysis, known steroid users were removed as they are less likely to be accessing structured drug treatment.

For methodological reasons the crossover between all three datasets will no longer be reported. Further information is available from the IAD manager if required.

NB: Numbers in brackets refer to the total reported for that service type, with steroid users omitted. These include the numbers appearing on the crossover sections. Analyses for the crossover areas are based on D(A)AT of Syringe Exchange site.

Fig 1: Crossover between Agency Syringe Exchange and NDTMS datasets

AGENCY
(56)

32 Male
9 Female

NDTMS
(889)

Fig 2: Crossover between Pharmacy Syringe Exchange and NDTMS datasets

PHARMACY
(68)

24 Male
2 Female

NDTMS
(889)